Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
US11389422B2 · kind B2 · utility
3Cited by
8References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 27, 2020 |
| Grant date | Jul 19, 2022 |
| Priority date | — |
| Expiry date | Apr 27, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N5/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.